--- title: "14:45 ETSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)" type: "News" locale: "en" url: "https://longbridge.com/en/news/281564567.md" description: "Class Action Attorney Juan Monteverde of Monteverde & Associates PC is investigating Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) regarding its merger with Korsana Biosciences, Inc. Cyclerion shareholders are expected to own about 1.5% of the combined company post-transaction. The firm, recognized for recovering millions for shareholders, offers free consultations for those concerned about the merger." datetime: "2026-04-02T18:47:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281564567.md) - [en](https://longbridge.com/en/news/281564567.md) - [zh-HK](https://longbridge.com/zh-HK/news/281564567.md) --- # 14:45 ETSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) , /PRNewswire/ -- **Class Action Attorney** Juan Monteverde **with** Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a **Top 50** **Firm** in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the **Empire State Building** in New York City and is investigating **Cyclerion Therapeutics, Inc. (NASDAQ:** **CYCN****)** related to its merger with Korsana Biosciences, Inc. Upon the closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company. **Is it a fair deal?** **Click here for more info** **https://monteverdelaw.com/case/cyclerion-therapeutics-inc/****. It is free and there is no cost or obligation to you.** **NOT ALL LAW FIRMS ARE EQUAL.** Before you hire a law firm, you should talk to a lawyer and ask: 1. Do you file class actions and go to Court? 2. When was the last time you recovered money for shareholders? 3. What cases did you recover money in and how much? **About Monteverde & Associates PC** Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. **No one is above the law.** If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our **website** or contact Juan Monteverde, Esq. either via e-mail at **\[email protected\]** or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC **The Empire State Building** 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America \[email protected\] Tel: (212) 971-1341 Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC ### Related Stocks - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [CYCN.US](https://longbridge.com/en/quote/CYCN.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md) - [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)